Abiopharma

BeOne apresenta dados históricos da Fase 3 em pacientes com LLC com mais de 80 anos na EHA 2026, reforçando os benefícios do BRUKINSA

BeOne presenta dati fondamentali di Fase 3 di pazienti affetti da CLL di età superiore agli 80 anni in occasione di EHA 2026, ribadendo il vantaggio di BRUKINSA

BeOne presenteert baanbrekende Fase 3-gegevens bij CLL-patiënten van 80 jaar en ouder op EHA 2026, waarmee het voordeel van BRUKINSA wordt bevestigd

Curatis verhoogt zijn omzetgroeiprognose voor 2026

À l’occasion du Visa Payments Forum, Visa annonce de nouvelles innovations en matière d’IA, de stablecoin et de jetons pour activer un commerce intelligent et programmable

Events and transactions

Eastern Bankshares, Inc. To Join S&P SmallCap 600® Index

SCE to Host Community Meeting as Support for Eaton Fire Recovery Continues

Scripps marks America’s 250th through powerful storytelling, special programming and community connection

Vontier Surpasses 2030 Emissions Target Five Years Early, Sets New 65% Reduction Goal